Identification of R146225 as a novel, orally active inhibitor of interleukin-5 biosynthesis

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 2, 2000, Pages 655-661

  Van Wauwe, J ^a   Aerts, F ^a   Cools, M ^a   Deroose, F ^a   Freyne, E ^a   Goossens, J ^a   Hermans, B ^a   Lacrampe, J ^a   Van Genechten, H ^a   Van Gerven, F ^a   Van Nyen, G ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; R 146225; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG IDENTIFICATION; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LOEFFLER PNEUMONIA; METABOLIC INHIBITION; MONONUCLEAR CELL; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL;

ADMINISTRATION, ORAL; ADULT; ANIMAL; CRYPTOCOCCOSIS; EOSINOPHILS; FEMALE; HUMAN; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-5; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PULMONARY EOSINOPHILIA; PYRIMIDINES; RNA, MESSENGER; SPLEEN; TRIAZINES;

EID: 0033776122     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibodies in mice: Prevention by high doses of methylprednisolone
2. SB207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions
3. Preclinical evaluation of anti-inflammatory activities of the novel pyrrolopyrimidine PNU-142731A, a potential treatment for asthma
4. Lack of immunosuppression by ketoconazole and itraconazole
5. The cells of the allergic response
6. Role of nuclear factor of activated T cells (NFAT) in expression of interleukin-5 and other cytokines involved in the regulation of hemopoietic cells
7. In vivo induction of interleukin-10 by anti-CD3 monoclonal antibody or bacterial liposaccharide: Differential modulation by cyclosporin A
8. Biology of interleukin-5 and its relevance to allergic diseases
9. Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo
10. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor
11. Pharmacology of the eosinophil
12. Role of IL-5 in the development of allergen-induced airway hyperresponsiveness
13. Cellular and molecular mechanisms involved in the regulation of eosinophil trafficking in vivo
14. Cytokines as targets for the inhibition of eosinophilic inflammation
15. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformaus infection in genetically susceptible mice (C57BL/6)
16. Pro-eosinophilic cytokines in asthma
17. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma
18. Effect of an orally active Th1/Th2 balance modulator, M50367, on IgE production, eosinophilia and airway hyperresponsiveness in mice
19. Correlation of house dust mite-specific lymphocyte proliferation with IL-5 production, eosinophilia and the severity of symptoms in infants with atopic dermatitis
20. IFN-gamma inhibits the development of secondary allergic responses in mice
21. Biology of IL-5 in health and disease
22. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma
23. Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids
24. IFN-γ receptor-deficient mice are hypersensitive to the anti-CD3-induced cytokine release syndrome and thymocyte apoptosis
25. The inhibition of interleukin 5 in allergic diseases
26. Binding of YY1 and Oct1 to a novel clement that downregulates expression of IL-5 in human T cells
27. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
28. Simple understanding and optimistic strategy for coping with atopic diseases
29. Regulation of antigen-induced human T-lymphocyte responses by calcineurin antagonists
30. Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in asthma
31. Inhibition of interleukin-5 gene expression by dexamethasone
32. Analysis of human IL-5 gene transcription by a novel nuclear run on method based on the polymerase chain reaction
33. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription
34. Nuclear factor of activated T cells and YY1 combine to repress IL-5 expression in a human T cell line
35. Bone marrow in allergic diseases: The role of interleukin-5 as an eosinophilopoietic factor
36. Interleukin-5 mRNA stability in haman T cells is regulated differently than interleukin-2, interleukin-3, interleukin-4, granulocyte/macrophage colonystimulating factor, and interferon-γ
37. Cytokine production by phytohemagglutinin -stimulated human blood cells: Effects of corticostereids, T cell immunosuppressants and phosphodiestorase IV inhibitors
38. Of the GATA-binding proteins, only GATA-4 selectively regulates the human interleukin-5 gone promoter in interleukin-5 producing cells which express multiple GATA-binding proteins